IRON Disc Medicine, Inc.

Nasdaq geminitherapeutics.com


$ 83.52 $ -0.27 (-0.32 %)    

Monday, 10-Nov-2025 15:59:59 EST
QQQ $ 621.14 $ 0.00 (0 %)
DIA $ 473.96 $ 0.00 (0 %)
SPY $ 680.16 $ 0.00 (0 %)
TLT $ 89.41 $ 0.00 (0 %)
GLD $ 380.75 $ 0.00 (0 %)
$ 83.58
$ 85.05
$ 72.13 x 6
$ 86.58 x 59
-- - --
$ 30.82 - $ 95.95
334,520
na
3.16B
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-21-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-11-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-31-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 03-10-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-29-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-buy-on-disc-medicine-raises-price-target-to-114

Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $...

 disc-medicine-q3-eps-177-misses-151-estimate

Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.5...

 disc-medicine-to-present-data-on-disc-0974-disc-3405-at-american-society-of-hematology-in-orlando

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commer...

 stifel-reinstates-buy-on-disc-medicine-announces-125-price-target

Stifel analyst Stephen Willey reinstates Disc Medicine (NASDAQ:IRON) with a Buy and announces $125 price target.

 morgan-stanley-maintains-overweight-on-disc-medicine-raises-price-target-to-115

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from ...

 disc-medicine-accelerates-late-stage-trials-for-anemia-and-blood-disorders-ahead-of-key-2026-data-targets-20252026-milestones-with-fda-backed-bitopertin-and-expanding-iron-regulation-pipeline

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commer...

 raymond-james-maintains-strong-buy-on-disc-medicine-raises-price-target-to-108

Raymond James analyst Michael Freeman maintains Disc Medicine (NASDAQ:IRON) with a Strong Buy and raises the price target fr...

 cantor-fitzgerald-maintains-overweight-on-disc-medicine-raises-price-target-to-153

Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target...

 fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

 disc-medicine-to-present-clinical-data-from-its-phase-1b-trial-of-disc-0974-at-upcoming-2025-american-society-of-nephrology-kidney-week-in-houston-texas-from-november-69-2025

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commer...

 wedbush-maintains-outperform-on-disc-medicine-raises-price-target-to-110

Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from ...

 disc-medicine-receives-fda-commissioners-national-priority-voucher-for-bitopertin-in-erythropoietic-protoporphyria-disc-is-seeking-accelerated-approval-of-bitopertin-for-patients-aged-12-years-and-older-with-epp-the-cnpv-program-is-designed-to-reduce-the-drug-application-review-process-to-1-2-months

WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical compa...

 morgan-stanley-maintains-overweight-on-disc-medicine-raises-price-target-to-90

Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from ...

 disc-medicine-q2-eps-158-misses-113-estimate

Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.58) per share which missed the analyst consensus estimate of $(1.1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION